Celsion Corporation (NASDAQ: CLSN), an oncology company dedicated to the development and commercialization of therapies for difficult-to-treat cancers, announced today that it has initiated a pivotal Phase I/II study of ThermoDox® in combination with hyperthermia, or heat, to treat recurrent chest wall breast cancer, a disease with a very poor patient prognosis and limited treatment options.

The open-label, dose-escalating pivotal trial has been designed to measure durable local complete response at the tumor site. Celsion expects to enroll approximately 100 patients across the United States and to complete the study by the first half of 2010. Study locations include the Florida Cancer Institute in Hudson, FL led by Principal Investigator Arthur Maztkowitz, MD, New York University Hospital in New York, NY led by Silvia Formenti, MD, and the Cancer Treatment Center of America in Tulsa, OK led by Petra Ketterl, MD. Additional information on the study may be found at http://www.clinicaltrials.gov.

Michael H. Tardugno, Celsion's President and Chief Executive Officer, commented "We are pleased to update our partners, particularly our shareholders, on the significant progress that has been made on our recurrent chest wall cancer program just three months after submitting our final protocol to the FDA. The clinical staff has brought us one step closer to delivering on the potential of ThermoDox to a cancer population that is truly in need of effective treatment options, given the debilitating nature of this disease, and we are extremely proud of their hard work and commitment to this initiative…